Company Profile
DermTech Stock Price, News & Analysis
- Ticker:
- DMTK
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for DMTK.
Company overview
Business overview
DermTech was a dermatology diagnostics company focused on noninvasive skin-cancer testing before its restructuring and decline. Its platform was built around molecular skin analysis.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ before restructuring, DermTech sat in diagnostics and dermatology testing.
Business Model Characteristics
The company depended on test adoption, reimbursement, and the commercialization of noninvasive dermatology diagnostics.
Position Within the Biotechnology Landscape
DermTech belongs to the historical diagnostics category rather than the current live public-company set.
Future catalysts
DermTech is now largely a closeout story, so the catalysts are any remaining strategic or asset-resolution update. The market no longer treats it as a live growth name.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does DermTech do?
DermTech was a dermatology diagnostics company focused on noninvasive skin-cancer testing before its restructuring and decline. Its platform was built around molecular skin analysis.
On which exchange is DMTK stock listed?
DermTech (DMTK) is associated with NASDAQ, United States, Biopharma.
What is DermTech?
DermTech is now largely a closeout story, so the catalysts are any remaining strategic or asset-resolution update.
Which conditions is DermTech targeting with DermTech?
DermTech is associated with cancer therapeutics, dermatology based on its company overview and current catalyst commentary.
How does DermTech describe recent progress with DermTech?
DermTech is now largely a closeout story, so the catalysts are any remaining strategic or asset-resolution update.
What future catalysts are investors watching for DermTech?
DermTech is now largely a closeout story, so the catalysts are any remaining strategic or asset-resolution update. The market no longer treats it as a live growth name.